3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Prostatic Neoplasms
6
Ovarian Neoplasms
6
Breast Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Neoplasm Metastasis
2
Fallopian Tube Neoplasms
2
Triple Negative Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
SCLC,Extensive Stage
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Mouth Neoplasms
1
Metastatic Castration-sensitive Prostate Cancer
1
Laryngeal Diseases
1
Hereditary Sensory and Autonomic Neuropathies
1
Hemangiosarcoma
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Biliary Tract Neoplasms
1
Interventions
Cyclophosphamide
3
fludarabine
2
Paclitaxel
2
Carboplatin
2
Bevacizumab
2
trastuzumab deruxtecan
1
pembrolizumab
1
olaparib
1
niraparib
1
mirvetuximab soravtansine
1
irinotecan sucrosofate
1
fludarabine phosphate
1
denileukin diftitox
1
Tinzaparin
1
Propranolol
1
Palliative Care
1
Nivolumab
1
Neoadjuvant Therapy
1
Music Therapy
1
Losartan
1
Indocyanine Green
1
GEN-1
1
Etodolac
1
E7777 fusion protein
1
Clarithromycin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Ovarian Epithelial
×
niraparib
×
30 days
×
Clear all
NCT06915025
2026-06-02
OVATION-3
Imunon
Phase 3
Recruiting
500 enrolled